- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05959083
Real World-studie av orala Upadacitinib-tabletter för att bedöma biverkningar och förändringar i sjukdomsaktivitet hos ungdomar och vuxna kinesiska deltagare med atopisk dermatit
En prospektiv, multicenter, observationsstudie efter marknadsföring för att utvärdera säkerheten och effektiviteten av upadacitinib hos kinesiska ungdomar och vuxna patienter med måttlig till svår atopisk dermatit (AD)
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. This study will assess how safe and effective upadacitinib is in treating AD in adolescent and adult Chinese participants.
Upadacitinib is an approved drug for treating AD. Approximately 200 adolescent and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in China.
Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed up for approximately 24 months per participant and 30 days after last treatment dose for safety data collection.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100191
- Peking University Third Hospital /ID# 257722
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350005
- The First Affiliated Hospital Of Fujian Medical University /ID# 257725
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510091
- Dermatology Hospital of Southern Medical University /ID# 261862
-
Shenzhen, Guangdong, Kina, 518033
- The Eighth Affiliated Hospital, Sun Yat-sen universtiy /ID# 257737
-
-
Henan
-
Zhengzhou, Henan, Kina, 450003
- People's Hospital of Henan Province /ID# 257736
-
-
Hubei
-
Wuhan, Hubei, Kina, 430022
- Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 257724
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110001
- First Affiliated Hospital of China Medical University /ID# 257641
-
-
Shaanxi
-
Xi'an, Shaanxi, Kina, 710004
- Second Affiliated Hospital of Xian Jiaotong University /ID# 257733
-
-
Shandong
-
Jinan, Shandong, Kina, 250022
- Shandong Dermatological Hospital /ID# 257727
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200040
- Huashan Hospital, Fudan University /ID# 256456
-
Shanghai, Shanghai Municipality, Kina, 200065
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 257726
-
Shanghai, Shanghai Municipality, Kina, 200443
- Shanghai Skin Disease Hospital /ID# 257719
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610017
- Chengdu Second Municipal People's Hospital /ID# 257732
-
Chengdu, Sichuan, Kina, 610041
- West China Hospital, Sichuan University /ID# 257720
-
Chengdu, Sichuan, Kina, 610072
- Sichuan Provincial People's Hospital /ID# 263898
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310003
- Hangzhou First People's Hospital /ID# 261867
-
Hangzhou, Zhejiang, Kina, 310009
- The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 257723
-
Ningbo, Zhejiang, Kina, 315010
- Ningbo First Hospital /ID# 263884
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Adolescent and adult Chinese participants with atopic dermatitis (AD) who are prescribed Upadacitinib by their physician according to their local label.
Beskrivning
Inclusion Criteria:
- Diagnosis of moderate to severe atopic dermatitis (AD) at the time of enrollment.
- Chinese adolescents (≥12 to <18 years of age with body weight of ≥40 kg) or adults (≥18 years of age) at the time of enrollment.
- Participants eligible for initiation of Upadacitinib treatment for AD, including any required screening tests indicated per China Label.
- The decision to prescribe Upadacitinib is made prior to and independently of study participation.
Exclusion Criteria:
- Participants who cannot be treated with Upadacitinib as per China label or by judgement of treating physician.
- Currently participating in any interventional research studies.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Upadacitinib
Adolescent and adult participants will receive upadacitinib as prescribed by their physician irrespective of the study participation. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of Participants With Incidence of Serious Infections
Tidsram: Up to approximately 25 months
|
Incidence rate of serious infections in AD participants treated with Upadacitinib will be assessed. |
Up to approximately 25 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: ABBVIE INC., AbbVie
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- P21-702
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .